DCM
AERI

Daruma Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Daruma Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-747,221
Closed -$35.5M – 40
2019
Q1 		$35.5M Buy
747,221
+281,240
+60% +$12.4M 4.04% 3
2018
Q4 		$16.8M Buy
465,981
+399,168
+597% +$18.7M 2.24% 26
2018
Q3 		$4.11M Buy
+66,813
New +$4.29M 0.39% 39

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Daruma Capital Management's AERI Position: Q2 2019 in Review

Daruma Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 747,221 shares — an estimated $35.5M sold.

Daruma Capital Management first reported a position in AERI in Q3 2018 and held it in 3 quarters. The position peaked at $35.5M in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • Daruma Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Daruma Capital Management sold 747,221 Aerie Pharmaceuticals shares in Q2 2019, an estimated $35.5M.
  • Daruma Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Daruma Capital Management's Aerie Pharmaceuticals position peaked at $35.5M in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Daruma Capital Management's 13F filing for Q2 2019.